儿童白血病中的JAK2:病变发生和药物开发的机制 - - 叙述性综述
1Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Annals of medicine and surgery (2012)
|June 9, 2025
概括
简氏激酶2 (JAK2) 突变通过激活信号通路来驱动小儿白血病. JAK2 抑制剂具有治疗潜力,但面临着挑战,需要结合策略来改善结果.
科学领域:
- 儿科瘤学 儿科瘤学
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 儿科白血病是一种常见的儿童癌症,具有复杂的分子基础.
- 简氏激酶2 (JAK2) 基因在白血病发生过程中起着至关重要的作用.
- 像V617F一样,JAK2突变与儿科白血病亚型有关,导致异常信号传递.
研究的目的:
- 为了研究JAK2突变在儿科白血病发病过程中的作用.
- 探索JAK2抑制剂在治疗儿科白血病中的治疗潜力.
- 确定克服与JAK2向治疗相关的挑战的策略.
主要方法:
- 在儿童白血病样本中分析JAK2基因突变.
- 在临床前和早期临床评估JAK2抑制剂 (例如,ruxolitinib,fedratinib).
- 研究涉及JAK2抑制剂的组合疗法.
主要成果:
- JAK2突变导致构成性JAK-STAT通路的激活,促进白血病细胞的增殖和存活.
- JAK2失调有助于支持骨髓微环境和免疫规避.
- JAK2 抑制剂显示有前途,但面临药物耐药性和非目标效应等局限性.
结论:
- 准JAK2通路是儿童白血病治疗的可行策略.
- 结合JAK2抑制剂和其他药物的组合疗法是必要的,以提高疗效和克服耐药性.
- 对新型药物配方和组合策略的进一步研究是有必要的.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K


